Pharma major Dr Reddy’s Laboratories is likely to post a dip in its consolidated net profit at about ₹1,040 crore in the fourth quarter ended March 31, 2026 compared to ₹1,587 crore in the corresponding quarter of last financial year on lower US sales, among others.
Speaking to businessline analysts said the total revenue of the Hyderabad based company is expected to decline in the range of 3 per cent to 3.75 per cent.
Dr Reddy’s will announced it Q4 and FY26 full years numbers on May 12, 2026.
The pharma major’s revenue for the quarter under review is expected to decline 3.35 per cent to ₹8,220 crore, on average, as compared to ₹8,506 crore in the corresponding quarter of the previous fiscal on higher freight rates due to the West Asian war, among others.
Shortly before the end of the quarter, Dr Reddy’s launched its injectable semaglutide under the brand name Obeda for the management of type 2 diabetes in the Indian market. It was the the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide. With this, the Hyderabad-based company made the first-day entry into the segment upon patent expiry.
Dr Reddy’s consolidated net profit increased 21 per cent in the fourth quarter ended March 31, 2025 at ₹1,587 crore against ₹1,307 crore in the corresponding period of previous financial year.
The total revenue increased 20 per cent at ₹8,506 crore in the period under review compared to ₹7,083 crore in the year-ago period.
For the full year FY25, it posted a 2 per cent increase in net profit at ₹5,655 crore on a 17 per cent growth in revenue at ₹3,255.4 crore.